PriZm Therapeutics
1 known investors
Find your way into PriZm Therapeutics
PriZm Tx develops treatments for rare genetic disorders, with a focus on MCT8 Deficiency (AHDS), an ultra-rare condition affecting boys. Its lead candidate is a first-in-class therapy for this disorder.
Investors · 1
Competitors · 2
by search overlap
Oup8 shared keywordsOxford University Press (OUP) provides dictionary data, language datasets, and lexical content in over 60 languages to power digital literacy tools, educational software, gaming platforms, and media experiences. The company works across reading apps, word games, quiz shows, and broadcast media to expand access to language learning and comprehension.
Fdna7 shared keywordsFDNA develops AI-powered diagnosis and care management tools that help parents, clinicians, and researchers identify developmental delays and rare genetic disorders early. The company serves patients, families, healthcare providers, and the pharmaceutical industry across 130+ countries using facial image analysis and genetic health risk assessment technology.
Companies competing with PriZm Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does PriZm Therapeutics do?
- PriZm Tx develops treatments for rare genetic disorders, with a focus on MCT8 Deficiency (AHDS), an ultra-rare condition affecting boys. Its lead candidate is a first-in-class therapy for this disorder.
- Who are PriZm Therapeutics's investors?
- PriZm Therapeutics's investors include The Innovation Space.